Discounted tickets are available now!
New York Professional Events List
TICKETED EVENTS*
LIFE SCIENCES, BIOTECHNOLOGY
TECHNOLOGY
FREE!
HEALTHCARE
SCIENCE AND TECHNOLOGY CONF...
ENVIRONMENT CONFERENCES
ARTS AND HUMANITIES CONFERE...
COMPUTERS AND INTERNET CONF...
HEALTH AND MEDICINE CONFERE...
BUSINESS & MANAGEMENT CONFE...
COMMUNICATIONS AND TRANSPOR...
SOCIETY CONFERENCES
EDUCATION CONFERENCES
SOCIAL SCIENCES CONFERENCES
NEWS CONFERENCES
ENERGY AND INDUSTRY CONFERE...
FINANCE
Please wait...
FDA's GMP Expectations for Phase I and First-in-Man Clinical Trials
Date
Nov 11, 2021 - 08:00 AM
- Nov 12, 08:00 AM
Link to Website
Organizer
Compliance Online
Venue
Courtyard Boston Cambridge
Location
777,
Memorial Dr
Cambridge,
MA,
USA,
ZIP: 02139
Phone:
Because a phase 1 clinical trial initially introduces an investigational new drug into human subjects, appropriate CGMP help ensure subject safety. It is important to implement quality control (QC) principles to the manufacture of phase 1 investigational drugs (i.e., interpreting and implementing CGMP consistent with good scientific methodology), which foster CGMP activities that are more appropriate for phase 1 clinical trials, improve the quality of phase 1 investigational drugs, and facilitate the initiation of investigational clinical trials in humans while continuing to protect trial subjects.
The following steps to establish the appropriate manufacturing environment for phase 1 investigational drugs should be taken:
A comprehensive and systematic evaluation of the manufacturing setting (i.e., product environment, equipment, process, personnel, materials) to identify potential hazards
Appropriate actions prior to and during manufacturing to eliminate or mitigate potential hazards to safeguard the quality of the phase 1 investigational drug
Review the FDA recommendations and requirements for implementing a compliant program for the phase 1 clinical program.
The following topics will be discussed to provide the foundation and basis for advancing drugs into clinical development from research and providing required information to the FDA regarding these products.
Overview of Good Manufacturing Practices
GMP Requirements for a Phase 1 Study
Seminar Fee Includes:
Lunch
AM-PM Tea/Coffee
Seminar Material
USB with seminar presentation
Hard copy of presentation
Attendance Certificate
$100 Gift Cert for next seminar
Download Brochure
Personnel
QC Function
Facility and Equipment
Control of components, containers and closures
Manufacturing & Records
Laboratory Controls
Vendor selection & management
Process Validation
Special Considerations
Multi-product facilities
Biologics
Sterile products
Combination products
Providing relevant information in the IND application
Course benefit:
This workshop will review the current regulations, guidance documents for early stage manufacturing and GMPs in detail. Regulatory strategies and logistical considerations for early development stage product, including vendor selection and management, stability, labeling, and documentation requirements will also be reviewed and explored.
Learning Objectives:
To gain an understanding of the requirements for drugs entering into phase 1 clinical development and the minimum FDA requirements for phase I GMPs. To learn practical applications for implementing manufacturing and quality strategies to meet FDA requirements.
Areas Covered:
Day 1 Topics
Overview of GMP requirements
GMP Requirements for a Phase 1 Study
Personnel documentation and requirements
QC Function procedures and requirements
Facility and Equipment requirements
Control of components, containers and closures – methods and specs
Manufacturing & Records during phase 1 studies with an eye toward later development
Day 2 Topics
Vendor selection & management
Process Validation to conduct for phase 1 clinical supply process
Specific requirements for various types of products: biologics, combinations, sterile products
Multi-product facilities considerations
Preparing relevant SOPs for early stage development
Providing relevant information in the IND application
Who will Benefit:
Directors
Manager
Supervisors
Lead workers in Regulatory Affairs Quality Assurance and Quality Control
Workers who will prepare GMP documents for early phase products
Workers who will review GMP documents for early phase products
Day 01(8:30 AM - 4:00 PM)
8:30 – 9:00 AM: Registration
9:00 – 10:30 AM: Good Manufacturing Practices & Phase 1 Requirements
Core principles of GMP
Detailed review of FDA phase 1 guidance document
10:30 – 10:45 AM: Break
10:45 – 12:30 noon: Good Manufacturing Practices & Phase 1 Requirements, continued
Acceptable practices and practical tips
GMP requirements for exploratory clinical studies
12:30 – 1:15 PM: Lunch
1:15 – 2:45 PM: Good Manufacturing Practices & Phase 1 Requirements, continued
Personnel documentation and requirements
Facility & equipment requirements
Control of components
Specific requirements for specialty products
2:45 – 3:00 PM: Break
3:00 – 4:00 PM: Vendor Selection and Management
Planning for the early stage with an eye towards large scale manufacturing
Vendor management
Raw material handling issues for early stage products
Day 02(8:30 AM - 4:00 PM)
8:30 – 10:00 AM: Overview of INDs Requirements & Expectations
FDA requirements for an IND submission
Expectations upon IND review
Format and content of the CMC section of an IND
10:00 – 10:15 AM: Break
10:15 – 12:00 noon: Overview of INDs Requirements & Expectations, continued
Characterization of the active ingredient and finished product
Various kinds of products: drugs, biologics, botanicals, diagnostics, medical devices
Manufacturing facility, personnel and equipment requirements
12:00 – 12:45 PM: Lunch
12:45 – 2:15 PM: Process Validation
Introduction to process validation for early stage manufacturers
Process validation reports and other documentation
2:15 – 2:30 PM: Break
2:30 – 4:00 PM: Creating SOPs Across all Stages of Development
What SOPs are required during early clinical development
When do additional SOPs need to be created
Ensuring that appropriate SOPs are in place for contractors
SOP processes and creation
QC function and responsibilities
Peggy J. Berry, MBA, RAC, is the President & CEO at Synergy Consulting where she provides consulting services to companies in all aspects of drug development. She also provides group and one-on-one training in drug development, regulatory affairs and project management topics. Prior to founding Synergy Consulting in 2020, she was Vice President of Regulatory Affairs at Insmed (2/2020-5/2020) where she was responsible for the development and implementation of global regulatory strategies and the management and oversight of the regulatory affairs department. Prior to Insmed, she was Vice President of Regulatory Affairs and Quality at Amarin (3/2009-2/2020). She has also held a variety of senior level positions at Dyax (5/2006-3/2009), MGI Pharma (now Eisai; 7/2005-5/2006), AstraZeneca (10/2001-7/2005), and Dey Pharma (now Mylan; 12/1997-10/2001). She has also held Regulatory Affairs roles within two clinical contract research organizations (ILEX Oncology and Cato Research Ltd; 1992-1997) and has worked in review divisions at the FDA (1985-1992). In addition, Ms. Berry consults for a number of companies in the regulatory and quality area, conducts a number of training courses, and is active in the Regulatory Affairs Professionals Society. She is the editor of the 2010 book "Choosing the Right Regulatory Career" (RAPS, MD) and author of the 2011 book "Communication & Negotiation" (RAPS, MD).
Please contact Marilyn Turner: Phone: +1 929 900 1853 Email: marilyn.turner [a] nyeventslist.com for registrations
The following steps to establish the appropriate manufacturing environment for phase 1 investigational drugs should be taken:
A comprehensive and systematic evaluation of the manufacturing setting (i.e., product environment, equipment, process, personnel, materials) to identify potential hazards
Appropriate actions prior to and during manufacturing to eliminate or mitigate potential hazards to safeguard the quality of the phase 1 investigational drug
Review the FDA recommendations and requirements for implementing a compliant program for the phase 1 clinical program.
The following topics will be discussed to provide the foundation and basis for advancing drugs into clinical development from research and providing required information to the FDA regarding these products.
Overview of Good Manufacturing Practices
GMP Requirements for a Phase 1 Study
Seminar Fee Includes:
Lunch
AM-PM Tea/Coffee
Seminar Material
USB with seminar presentation
Hard copy of presentation
Attendance Certificate
$100 Gift Cert for next seminar
Download Brochure
Personnel
QC Function
Facility and Equipment
Control of components, containers and closures
Manufacturing & Records
Laboratory Controls
Vendor selection & management
Process Validation
Special Considerations
Multi-product facilities
Biologics
Sterile products
Combination products
Providing relevant information in the IND application
Course benefit:
This workshop will review the current regulations, guidance documents for early stage manufacturing and GMPs in detail. Regulatory strategies and logistical considerations for early development stage product, including vendor selection and management, stability, labeling, and documentation requirements will also be reviewed and explored.
Learning Objectives:
To gain an understanding of the requirements for drugs entering into phase 1 clinical development and the minimum FDA requirements for phase I GMPs. To learn practical applications for implementing manufacturing and quality strategies to meet FDA requirements.
Areas Covered:
Day 1 Topics
Overview of GMP requirements
GMP Requirements for a Phase 1 Study
Personnel documentation and requirements
QC Function procedures and requirements
Facility and Equipment requirements
Control of components, containers and closures – methods and specs
Manufacturing & Records during phase 1 studies with an eye toward later development
Day 2 Topics
Vendor selection & management
Process Validation to conduct for phase 1 clinical supply process
Specific requirements for various types of products: biologics, combinations, sterile products
Multi-product facilities considerations
Preparing relevant SOPs for early stage development
Providing relevant information in the IND application
Who will Benefit:
Directors
Manager
Supervisors
Lead workers in Regulatory Affairs Quality Assurance and Quality Control
Workers who will prepare GMP documents for early phase products
Workers who will review GMP documents for early phase products
Day 01(8:30 AM - 4:00 PM)
8:30 – 9:00 AM: Registration
9:00 – 10:30 AM: Good Manufacturing Practices & Phase 1 Requirements
Core principles of GMP
Detailed review of FDA phase 1 guidance document
10:30 – 10:45 AM: Break
10:45 – 12:30 noon: Good Manufacturing Practices & Phase 1 Requirements, continued
Acceptable practices and practical tips
GMP requirements for exploratory clinical studies
12:30 – 1:15 PM: Lunch
1:15 – 2:45 PM: Good Manufacturing Practices & Phase 1 Requirements, continued
Personnel documentation and requirements
Facility & equipment requirements
Control of components
Specific requirements for specialty products
2:45 – 3:00 PM: Break
3:00 – 4:00 PM: Vendor Selection and Management
Planning for the early stage with an eye towards large scale manufacturing
Vendor management
Raw material handling issues for early stage products
Day 02(8:30 AM - 4:00 PM)
8:30 – 10:00 AM: Overview of INDs Requirements & Expectations
FDA requirements for an IND submission
Expectations upon IND review
Format and content of the CMC section of an IND
10:00 – 10:15 AM: Break
10:15 – 12:00 noon: Overview of INDs Requirements & Expectations, continued
Characterization of the active ingredient and finished product
Various kinds of products: drugs, biologics, botanicals, diagnostics, medical devices
Manufacturing facility, personnel and equipment requirements
12:00 – 12:45 PM: Lunch
12:45 – 2:15 PM: Process Validation
Introduction to process validation for early stage manufacturers
Process validation reports and other documentation
2:15 – 2:30 PM: Break
2:30 – 4:00 PM: Creating SOPs Across all Stages of Development
What SOPs are required during early clinical development
When do additional SOPs need to be created
Ensuring that appropriate SOPs are in place for contractors
SOP processes and creation
QC function and responsibilities
Peggy J. Berry, MBA, RAC, is the President & CEO at Synergy Consulting where she provides consulting services to companies in all aspects of drug development. She also provides group and one-on-one training in drug development, regulatory affairs and project management topics. Prior to founding Synergy Consulting in 2020, she was Vice President of Regulatory Affairs at Insmed (2/2020-5/2020) where she was responsible for the development and implementation of global regulatory strategies and the management and oversight of the regulatory affairs department. Prior to Insmed, she was Vice President of Regulatory Affairs and Quality at Amarin (3/2009-2/2020). She has also held a variety of senior level positions at Dyax (5/2006-3/2009), MGI Pharma (now Eisai; 7/2005-5/2006), AstraZeneca (10/2001-7/2005), and Dey Pharma (now Mylan; 12/1997-10/2001). She has also held Regulatory Affairs roles within two clinical contract research organizations (ILEX Oncology and Cato Research Ltd; 1992-1997) and has worked in review divisions at the FDA (1985-1992). In addition, Ms. Berry consults for a number of companies in the regulatory and quality area, conducts a number of training courses, and is active in the Regulatory Affairs Professionals Society. She is the editor of the 2010 book "Choosing the Right Regulatory Career" (RAPS, MD) and author of the 2011 book "Communication & Negotiation" (RAPS, MD).
Please contact Marilyn Turner: Phone: +1 929 900 1853 Email: marilyn.turner [a] nyeventslist.com for registrations